Molecular diagnostics (Cepheid): FDA clearance for the Xpert GI Panel, a multiplex PCR test that detects 11 gastrointestinal pathogens from a single sample using the GeneXpert platform.Diagnostics (Beckman Coulter Diagnostics): Expansion of the DxI 9000 assay menu, including progress in neurodegenerative disease and a first-to-market automated high-throughput BD-Tau research-use-only immunoassay, alongside additions in cardiac and blood virus menus.Life sciences (SCIEX): Introduction of the ZenoTOF 8600 mas ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Speaker2Good day, everyone. My name is Nikki, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's fourth quarter 2025 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star, ...

(GAAP)**|**20.40%**||**24.90%**||**12.00%**||**26.80%**||Full year 2025 impact from operating profit margins ofbusinesses that have been owned for less than one yearor were disposed of during such period and did notqualify as discontinued operations|(0.20)||—||(0.30)||(0.15)||Full year 2025 resolution of an acquisition contingency inthe Diagnostics segment|0.05||—||—||0.10||Full year 2025 impairment charges related to tradenames in the Life Sciences and Diagnostics segmentsand technology, other intangible a ...